ATE425151T1 - Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen - Google Patents

Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen

Info

Publication number
ATE425151T1
ATE425151T1 AT04725892T AT04725892T ATE425151T1 AT E425151 T1 ATE425151 T1 AT E425151T1 AT 04725892 T AT04725892 T AT 04725892T AT 04725892 T AT04725892 T AT 04725892T AT E425151 T1 ATE425151 T1 AT E425151T1
Authority
AT
Austria
Prior art keywords
triazinees
racemat
diamino
dihydro
cleavage
Prior art date
Application number
AT04725892T
Other languages
English (en)
Inventor
Gerard Moinet
Daniel Cravo
Thierry Passemar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE425151T1 publication Critical patent/ATE425151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04725892T 2003-04-10 2004-04-06 Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen ATE425151T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0304486A FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Publications (1)

Publication Number Publication Date
ATE425151T1 true ATE425151T1 (de) 2009-03-15

Family

ID=33041769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725892T ATE425151T1 (de) 2003-04-10 2004-04-06 Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen

Country Status (23)

Country Link
US (1) US7501511B2 (de)
EP (1) EP1611111B1 (de)
JP (1) JP4836778B2 (de)
KR (1) KR101107665B1 (de)
CN (1) CN100383130C (de)
AR (1) AR044511A1 (de)
AT (1) ATE425151T1 (de)
AU (1) AU2004228125B2 (de)
BR (1) BRPI0409258B8 (de)
CA (1) CA2521879C (de)
CY (1) CY1109609T1 (de)
DE (1) DE602004019897D1 (de)
DK (1) DK1611111T3 (de)
ES (1) ES2321718T3 (de)
FR (1) FR2853650B1 (de)
MX (1) MXPA05010764A (de)
PL (1) PL214955B1 (de)
PT (1) PT1611111E (de)
RU (1) RU2344131C2 (de)
SI (1) SI1611111T1 (de)
TW (1) TWI344464B (de)
WO (1) WO2004089917A2 (de)
ZA (1) ZA200509071B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
CN101468986B (zh) * 2007-12-26 2010-12-29 香港南北兄弟国际投资有限公司 一种二氢嘧啶消旋化合物的拆分方法
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
SI2300444T1 (sl) * 2008-05-23 2016-10-28 Poxel Sas Proces za sintezo derivatov 3,6-dihidro-1,3,5-triazina
ES2569105T3 (es) 2008-07-29 2016-05-06 Poxel Procedimiento para aislar componentes enantiómeros a partir de mezclas de enantiómeros por cristalización controlada por tamaño de partícula
DE102009014898A1 (de) * 2009-03-25 2010-09-30 Merck Patent Gmbh Prozess zur Enantiomerentrennung von 3,6-Dihydro-1,3,5-triazinderivaten
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
EP2579879B1 (de) * 2010-06-09 2016-03-23 Poxel Triazin derivate zur verzögerung der entstehung von typ-1-diabetes
CN103228635B (zh) * 2010-12-01 2016-03-30 珀科赛尔 利用酒石酸分离三嗪衍生物对映异构体
BR112020006472A2 (pt) 2017-10-02 2020-10-06 Poxel método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep)
CN111918655B (zh) 2018-06-06 2024-05-31 博希尔公司 治疗患有慢性肾脏疾病的糖尿病受试者的方法
KR20210003786A (ko) 2018-06-14 2021-01-12 폭셀 당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정
CN115087643B (zh) * 2021-01-15 2023-10-27 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894027A (en) * 1973-07-31 1975-07-08 Merck & Co Inc Resolution of racemic reticuline and racemization of its enantiomers
JPS5414986A (en) 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
JPH0436279A (ja) * 1990-06-01 1992-02-06 Kyowa Hakko Kogyo Co Ltd 光学活性なベンゾオキセピン誘導体の製造法
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
AU7000696A (en) * 1995-09-22 1997-04-09 Fujisawa Pharmaceutical Co., Ltd. Novel processes for producing pyridoindole derivatives
MX9805870A (de) * 1996-01-22 1999-01-31
JPH11193270A (ja) * 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
JP4138928B2 (ja) * 1998-02-20 2008-08-27 山川薬品工業株式会社 Ｄ−アロイソロイシンの製造方法および製造の中間体
FR2775974B1 (fr) * 1998-03-16 2000-08-18 Rhodia Chimie Sa Procede de separation de diastereoisomeres d'une diphosphine et preparation de diphosphines optiquement actives
AU4698399A (en) * 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
JP2001199972A (ja) * 2000-01-20 2001-07-24 Eisai Co Ltd 光学活性ピペラジン誘導体の製造法
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
JP2002193933A (ja) * 2000-06-14 2002-07-10 Toray Ind Inc 光学活性ピペリジン誘導体またはその酸塩の製造方法
DE10042064A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10125131A1 (de) * 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram

Also Published As

Publication number Publication date
BRPI0409258B8 (pt) 2021-05-25
CY1109609T1 (el) 2014-08-13
US7501511B2 (en) 2009-03-10
EP1611111B1 (de) 2009-03-11
AR044511A1 (es) 2005-09-14
CN100383130C (zh) 2008-04-23
CA2521879A1 (en) 2004-10-21
RU2005134685A (ru) 2006-06-10
FR2853650B1 (fr) 2006-07-07
PL377833A1 (pl) 2006-02-20
BRPI0409258A (pt) 2006-03-28
CN1771233A (zh) 2006-05-10
BRPI0409258B1 (pt) 2018-05-15
AU2004228125A1 (en) 2004-10-21
TW200504037A (en) 2005-02-01
DK1611111T3 (da) 2009-05-18
JP4836778B2 (ja) 2011-12-14
HK1088002A1 (en) 2006-10-27
ES2321718T3 (es) 2009-06-10
JP2006522753A (ja) 2006-10-05
WO2004089917A3 (en) 2004-12-23
RU2344131C2 (ru) 2009-01-20
PL214955B1 (pl) 2013-10-31
MXPA05010764A (es) 2005-12-12
US20060223803A1 (en) 2006-10-05
EP1611111A2 (de) 2006-01-04
TWI344464B (en) 2011-07-01
CA2521879C (en) 2013-01-08
WO2004089917A2 (en) 2004-10-21
PT1611111E (pt) 2009-06-18
KR20050120791A (ko) 2005-12-23
SI1611111T1 (sl) 2009-08-31
FR2853650A1 (fr) 2004-10-15
KR101107665B1 (ko) 2012-01-20
AU2004228125B2 (en) 2010-07-15
DE602004019897D1 (de) 2009-04-23
ZA200509071B (en) 2007-04-25

Similar Documents

Publication Publication Date Title
ATE425151T1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen
DE60319325D1 (de) Verfahren zur Herstellung von hydriertem Nitrilkautschuk mit niedrigem Molekulargewicht
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE435012T1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE478082T1 (de) Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
EP1572075A4 (de) Verfahren zur behandlung von krankheiten in verbindung mit abnormaler kinasewirkung
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
EP1569695A4 (de) Antisense-modulationder apolipoprotein-b-expression
DE602004010234D1 (de) Verfahren zur herstellung von 4-aminodiphenylamin
DE602005026987D1 (de) Verfahren zur herstellung von 1,2-dichlorethan
DE602004012746D1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicycloä3,1,0ühexane-2-carboxamide,n-ä3-amino-1-(cyclobutylmethyl)-2,3-dioxopropylü ü-3-ä(2s)-2-äää1,1-dimethylethylüaminoücarbonylaminoü-3,3-dimethyl-1-oxobutylü-6,6-dimethyl
EP1569500A4 (de) Verfahren zur herstellung von elektrolumineszenten vorichtungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE602004014805D1 (de) Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
DE602005011814D1 (de) Verfahren zur herstellung von enantiomerreinen 1,1'-spirobiindan-6,6'-diol-derivaten
DE60335766D1 (de) Verfahren zur Herstellung von m-Xylylendiamin
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1611111

Country of ref document: EP

EEIH Change in the person of patent owner